Formulary Drug Review: Rezafungin-Reference-Cited by-同舟云学术

Formulary Drug Review: Rezafungin

Published:2023-10-30 Issue: Volume: Page:
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Kessel Brittney¹,Baker Danial E.¹^ORCID

Affiliation:

1. Washington State University, Spokane, WA, USA

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1177/00185787231206523

Reference25 articles.

1. Rezzayo (rezafungin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics LLC; March 2023.

2. Cidara Therapeutics. ReSTORE phase 3 trial results for rezafungin. Published December 2021. Accessed April 13, 2023. https://docs.publicnow.com/viewDoc?hash_primary=5E72A6C4EAF1BF7B8F137A503B759818BD2521CA

3. Cidara Therapeutics. Study of rezafungin compared to standard antimicrobial regimen for prevention of invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation (ReSPECT). ClinicalTrials.gov identifier: NCT04368559. Updated April 27, 2023. Accessed May 25, 2023. https://clinicaltrials.gov/ct2/show/NCT04368559

4. Cancidas (caspofungin) [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; May 2022.

5. Eraxis (anidulafungin) [prescribing information]. New York, NY: Roerig; October 2020.